In January 2021, Beijing Targeting One Biotechnology Co., Ltd. (hereinafter referred to as " Targeting One") announced the completion of 150 million round B financing.

There is a vaccine race, but not between countries. It is a race between humans to develop vaccines and novel coronavirus.

Recently, Shanghai Runda Medical Technology Co., Ltd. disclosed to the public that the company will acquire part of the shares of two IVD companies in Anhui and Shanghai at a price of 328 million.

Till this report, there are 14 Chinese IVD enterprise successfully developed the B.1.1.7 testing kits.

The State Council Information Office P.R.C.announced that the Sinopharm COVID-19 Vaccine has been approved.

2020 has been a magical year for the in vitro diagnostic industry. How will history record the year 2020?

Vazyme's IPO was Accepted, Planning to Raise 1.225 Billion Yuan; Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China.

Another Capital Raising Boom in in vitro diagnostic industry.

In recent years, because of the optimistic attitude about the development of IVD industry, various VC and PE investments are very active.

On December 19, at the 16th International Respiratory Symposium in Changshu, Abbott announced that it had joined the International Smart Health Alliance and signed an important strategic cooperation with the China Lung Cancer Prevention Alliance.

On December 18, 2020, Hipro biotechnology Corp announced the completion of the c-round financing of over 100 million YUAN.

CSRC has approved the registration of the initial public offering of Jiangsu HOB Biotech (HOB) Co., Ltd. on the science and technology innovation board.

Recently, TüV SüD Product Service GmbH an EU Notified Body certified the first IVDR CE certificate in the field of chemiluminescence in China, and its winner is Shenzhen New Industries Biomedical Engineering Co., Ltd.

On December 8, 2020, Beckman Coulter, Inc. and Realcan signed a strategic cooperation agreement in Shanghai and held a cooperation exchange meeting.

Maccura and Hoyotek Bio obtained the CE for their COVID-19 products.